Mn Services Vermogensbeheer B.V. Purchases 1,900 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mn Services Vermogensbeheer B.V. increased its Thermo Fisher Scientific position by 1.8%, purchasing 1,900 shares to hold 110,115 shares valued at approximately $74.3 million. Institutional investors and hedge funds collectively own 89.23% of the company.
• Thermo Fisher reported quarterly revenue of $11.99 billion and EPS of $6.03, exceeding analyst estimates, while revenue rose 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts hold a consensus “Moderate Buy” rating with a $634.86 target price, but insider selling and valuation concerns remain risks; executives sold approximately 73,768 shares worth $44.1 million over the past 90 days.

Mn Services Vermogensbeheer B.V. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,115 shares of the medical research company's stock after purchasing an additional 1,900 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Thermo Fisher Scientific were worth $74,333,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Legacy Wealth Managment LLC ID grew its holdings in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after purchasing an additional 22 shares during the last quarter. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $26,000. MBM Wealth Consultants LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at $29,000. Finally, Pingora Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $651.63 on Friday. The firm has a 50 day moving average of $625.73 and a 200-day moving average of $540.54. The company has a market cap of $240.94 billion, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 2.77 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $694.33.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the company earned $4.28 EPS. Thermo Fisher Scientific's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. BMO Capital Markets lowered Thermo Fisher Scientific to a "market perform" rating in a research note on Wednesday, September 9th. UBS Group upgraded Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and upped their target price for the company from $540.00 to $730.00 in a report on Tuesday, September 8th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $634.86.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher helped launch the Digital CMC Consortium, bringing biopharma companies, technology providers and regulators together to establish digital standards for chemistry, manufacturing and controls data. The initiative could support faster drug development, more efficient regulatory reviews and recurring digital lifecycle-management opportunities. What Could Thermo Fisher Scientific Change With Its New Digital CMC Consortium?
• Positive Sentiment: Thermo Fisher’s clinical research business signed an agreement with Quantum BioPharma to support a Phase 2 multiple sclerosis trial for Lucid-MS. The contract reinforces demand for the company’s contract research services, although the near-term financial impact was not disclosed. Quantum BioPharma Enlists Thermo Fisher’s Clinical Research Business
• Neutral Sentiment: Industry reports project strong long-term growth in pharmaceutical contract research, PCR testing and cell-based assay markets, where Thermo Fisher is a major participant. These reports improve the sector’s growth backdrop but do not represent new company guidance or orders. Pharmaceutical CRO Market Forecasts Growth PCR Market Report Forecasts Growth
• Negative Sentiment: Profit-taking is likely after a strong rally supported by Thermo Fisher’s prior earnings beat. With the next results approaching, investors may be waiting for confirmation that biopharma and laboratory spending remain strong enough to justify the stock’s elevated valuation.
• Negative Sentiment: Quiver Quantitative reported that insiders made no open-market purchases and recorded 94 sales over the past six months, including substantial sales by senior executives. Recent analyst price targets cited in the report were generally below the prevailing share price, which may reinforce valuation concerns. The data should be interpreted cautiously because insider sales can reflect compensation and diversification.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.